Company Profiles

driven by the PitchBook Platform

Accium BioSciences

Accium BioSciences
2004 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Conv. Debt LATEST DEAL TYPE
$250K LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's TemodarĀ® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-TemodarĀ® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Social/Platform Software
Primary Office
550 17th Avenue
Suite 550
Seattle, WA 98122
United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Accium BioSciences’s full profile, request a free trial.

Accium BioSciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Convertible Debt 19-Nov-2008 $250K 00.000 Completed Startup
2. Early Stage VC (Series A) 01-Jan-2007 00.000 00.000 00.000 Completed Startup
1. Convertible Debt 06-Jul-2004 $500K $500K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Accium BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Accium BioSciences Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alliance of Angels Angel Group Minority 000 0000 000000 0
Sabey Corporation Minority 000 0000 000000 0
WRF Capital Venture Capital Minority 000 0000 000000 0

Accium BioSciences Executive Team (5)

Name Title Board
Seat
Contact
Info
Jonathan Adler Study Director
Glenn Kawasaki Ph.D Chief Executive Officer & President
Barbara Alford-Cassel Vice President, Quality Assurance & Quality Assurance Officer

2 Former Executives

You’re viewing 3 of 5 executives. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com